文献速递冠心病

经导管主动脉瓣置换术后短期并发症的系统综述与荟萃分析

Short‐Term Complications of Transcatheter Aortic Valve Replacement: A Systematic Review and Meta‐Analysis (PROLONG‐TAVR)
RSS 订阅 · Catheterization and Cardiovascular Interventions · 2026-10-15

本研究对2002年至2024年5月发表的242项观察性研究、共181187例接受经导管主动脉瓣置换术的重度主动脉瓣狭窄患者进行系统综述与荟萃分析。结果显示,新一代瓣膜的短期并发症总体减少,SAPIEN 3的中重度瓣周漏和卒中发生率最低,ACURATE neo2的永久起搏器植入率最低。

要点

  • SAPIEN 3的中重度瓣周漏和卒中发生率在纳入瓣膜中最低。
  • ACURATE neo2的永久起搏器植入率最低,为7.7%。
  • 自膨式瓣膜瓣周漏更常见,球扩式瓣膜永久起搏器植入总体更少。

核心结论

  • 新一代经导管心脏瓣膜的短期并发症总体较前代减少。
  • 中重度瓣周漏在自膨式瓣膜中仍更常见,永久起搏器植入是最高发的短期并发症。
  • 卒中发生率在新一代瓣膜间变化不大,瓣环破裂、冠状动脉阻塞和瓣膜栓塞均罕见,发生率均低于1%。

研究设计与样本

  • 本研究为系统综述与荟萃分析,遵循PRISMA规范并在PROSPERO前瞻注册。
  • 纳入2002年至2024年5月发表的观察性研究,对象为接受经导管主动脉瓣置换术的重度主动脉瓣狭窄患者。
  • 共纳入242项研究、181187例患者,以经股动脉入路为主,并要求研究报告特定瓣膜类型的并发症。

主要发现

  • SAPIEN 3的中重度瓣周漏发生率为1.04%(95% CI 0.69–1.55),卒中发生率为1.87%(95% CI 1.64–2.14),均为纳入瓣膜中最低。
  • ACURATE neo2的永久起搏器植入率为7.7%(95% CI 5.82–10.11),为纳入瓣膜中最低。
  • Evolut PRO和SAPIEN 3的主要血管并发症发生率分别为3.56%(95% CI 2.77–4.57)和3.87%(95% CI 3.22–4.66)。
  • Evolut PRO和SAPIEN 3的主要或危及生命出血发生率分别为2.96%(95% CI 2.09–4.17)和4.8%(95% CI 4.04–5.69)。

关键数值与推荐

  • 中重度瓣周漏最低为SAPIEN 3:1.04%(95% CI 0.69–1.55)。
  • 卒中最低为SAPIEN 3:1.87%(95% CI 1.64–2.14)。
  • 永久起搏器植入最低为ACURATE neo2:7.7%(95% CI 5.82–10.11)。
  • 主要血管并发症:Evolut PRO为3.56%(95% CI 2.77–4.57),SAPIEN 3为3.87%(95% CI 3.22–4.66)。
  • 主要或危及生命出血:Evolut PRO为2.96%(95% CI 2.09–4.17),SAPIEN 3为4.8%(95% CI 4.04–5.69)。

临床怎么用

  • 选择经导管心脏瓣膜时可将SAPIEN 3作为降低中重度瓣周漏和卒中风险的参考。
  • 如需降低永久起搏器植入风险,可优先考虑ACURATE neo2。
  • 瓣环破裂、冠状动脉阻塞和瓣膜栓塞发生率均低于1%,属罕见并发症。

局限性

  • 纳入研究均为观察性研究,存在选择偏倚和混杂因素的可能。
  • 原方案计划同时评价长期并发症,但长期结局数据稀疏且报告不一致,无法进行稳健合并分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT To estimate the cumulative incidence of short-term complications across different transcatheter heart valve (THV) prostheses used for transcatheter aortic valve replacement (TAVR). We performed a systematic review and meta-analysis in accordance with PRISMA and a prospectively registered PROSPERO protocol. Observational studies published from 2002 through May 2024 that included patients with severe aortic stenosis undergoing predominantly transfemoral TAVR and reported prosthesis-specific complications were eligible. Although the original protocol intended to evaluate both short- and long-term complications, long-term outcomes were too sparse and inconsistently reported for robust pooled analyses; therefore, the present analysis focuses on short-term complications. Pooled cumulative incidences were calculated using random-effects models. We included 242 studies comprising 181,187 patients. SAPIEN 3 had the lowest incidence of moderate-to-severe paravalvular leak (PVL) (1.04%, 95% CI 0.69–1.55) and stroke (1.87%, 95% CI 1.64–2.14), whereas ACURATE neo2 had the lowest incidence of permanent pacemaker implantation (PPI) (7.7%, 95% CI 5.82–10.11). Evolut PRO and SAPIEN 3 showed among the lowest rates of major vascular complications (3.56%, 95% CI 2.77–4.57 and 3.87%, 95% CI 3.22–4.66, respectively) and major or life-threatening bleeding (2.96%, 95% CI 2.09–4.17 and 4.8%, 95% CI 4.04–5.69, respectively). Short-term complications have decreased with newer-generation THV prostheses. PVL remains more frequent with self-expanding valves, whereas PPI is the most frequent complication and is generally less frequent with balloon-expandable valves and ACURATE neo2. Stroke rates have changed little across newer generations, and annular rupture, coronary artery obstruction, and valve embolization remain rare (< 1%).

来源:Catheterization and Cardiovascular Interventions,查看原文。版权归原作者所有。

引用

  1. Catheterization and Cardiovascular Interventions:Short‐Term Complications of Transcatheter Aortic Valve Replacement: A Systematic Review and Meta‐Analysis (PROLONG‐TAVR)

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。